데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
41100-52-1CC12CC3CC(C)(C1)CC([NH3+])(C3)C2.[Cl-]LDDHMLJTFXJGPI-UHFFFAOYSA-N41100-52-1Crystalline Solid
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Memantine, a NMDA receptor antagonist, was co-developed by Forest Laboratories with Merz Pharmaceuticals and marketed under the trade name Namenda for the treatment of Alzheimer’s disease in the US after its approval in October, 2003. This drug has been available in many European and Asian markets before getting approval in the US.
용도Used as an antiparkinsonian and antispasmodic
일반 설명Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.Memantine Hydrochloride is a drug used for treating the Alzheimer′s disease by means of reducing abnormal activity in the brain. It can help patients suffering from dementia as it assists them to think more clearly and perform their chores with ease.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…
정의ChEBI: A hydrochloride obtained by reaction of memantine with one equivalent of hydrochloric acid. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.